Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorBRUN, Jean-Luc
dc.contributor.authorRAJAONARISON, Jose
dc.contributor.authorNOCART, Nicolas
dc.contributor.authorHOARAU, Laura
dc.contributor.authorBRUN, Stéphanie
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorGARRIGUE, Isabelle
IDREF: 12258953X
dc.date.accessioned2023-11-17T16:28:05Z
dc.date.available2023-11-17T16:28:05Z
dc.date.issued2018-02-01
dc.identifier.issn2049-9450en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/184830
dc.description.abstractEnTargeted immunotherapy of high-grade cervical intra-epithelial neoplasia (CIN) has been developed as an alternative to conization, to preserve future reproductive outcomes and avoid human papillomavirus (HPV) persistence. The objectives of the review are to present drugs according to their process of development and to examine their potential future use. A search for key words associated with CIN and targeted immunotherapy was carried out in the Cochrane library, Pubmed, Embase, and ClinicalTrials.gov from 1990 to 2016. Publications (randomized, prospective and retrospective studies) in any language were eligible for inclusion, as well as ongoing trials registered on the ClinicalTrials.gov website. Targeted immunotherapy includes peptide/protein-based vaccines, nucleic acid-based vaccines (DNA), and live vector-based vaccines (bacterial or viral). A total of 18 vaccines were identified for treatment of CIN at various stages of development, and the majority were well-tolerated. Adverse effects were primarily injection site reactions and flu-like symptoms under grade 2. The efficacy of vaccines defined by regression of CIN2/3 to no CIN or CIN1 ranged from 17 to 59% following a minimum of a 12-week follow-up. In the majority of studies, there was no association demonstrated between histological response and HPV clearance, or between histological or virological response and immune T cell response. Given that the spontaneous regression of CIN2/3 is 20-25% at 6 months, targeted immunotherapy occurs an additional value, which never reaches 50%, with one trial an exception to this. However, research and development on HPV eradication drugs needs to be encouraged, due to HPV-associated disease burden.
dc.language.isoENen_US
dc.subject.entargeted immunotherapy
dc.subject.enhigh-grade cervical intra-epithelial neoplasia
dc.subject.enhuman papillomavirus
dc.title.enTargeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials.
dc.title.alternativeMol Clin Oncolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3892/mco.2017.1531en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
dc.identifier.pubmed29435283en_US
bordeaux.journalMolecular and Clinical Oncologyen_US
bordeaux.page227-235en_US
bordeaux.volume8en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue2en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04292592
hal.version1
hal.date.transferred2023-11-17T16:28:07Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Molecular%20and%20Clinical%20Oncology&rft.date=2018-02-01&rft.volume=8&rft.issue=2&rft.spage=227-235&rft.epage=227-235&rft.eissn=2049-9450&rft.issn=2049-9450&rft.au=BRUN,%20Jean-Luc&RAJAONARISON,%20Jose&NOCART,%20Nicolas&HOARAU,%20Laura&BRUN,%20St%C3%A9phanie&rft.genre=article


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée